New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
12:00 EDTAGIOAgios Pharmaceuticals rises 23.4%
Agios Pharmaceuticals is up 23.4%, or $8.33, to $43.91
News For AGIO From The Last 14 Days
Check below for free stories on AGIO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
16:04 EDTAGIOAgios Pharmaceuticals files to sell 2M shares of common stock
Subscribe for More Information
April 17, 2014
08:04 EDTAGIOAgios initiates AG-348 Phase 1 study
Agios Pharmaceuticals announced dose administration of AG-348 in a Phase 1 study in healthy volunteers. AG-348 is an orally available, potent, selective small molecule activator of pyruvate kinase-R, a metabolic enzyme, which, when mutated, leads to pyruvate kinase deficiency, a rare, inherited hemolytic anemia. AG-348 is wholly owned by Agios, with the company maintaining full worldwide development and commercialization rights. The company said, “Preclinical studies have demonstrated that AG-348 activates a broad spectrum of PK-R mutant proteins, and corrects the metabolic defects found in patient-derived blood samples. These data support the hypothesis that drug intervention with AG-348 will restore glycolytic pathway flux and normalize red blood cell metabolism. Because AG-348 directly targets the underlying disease, it has the potential to be an important treatment option for patients with PK deficiency.”
April 10, 2014
09:00 EDTAGIOAgios Pharmaceuticals falls 5%
Agios Pharmaceuticals is down 5%, or $2.42, to $46.00
06:16 EDTAGIOAgios Pharmaceuticals files to sell $75M in common stock
JPMorgan and Goldman are acting as joint booking running managers for the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use